Aurobindo Pharma Approves Merger of Wholly Owned API Subsidiaries
Aurobindo Pharma Ltd 路 Others (Uncategorized) 路 05 Nov 2026, 1:58 am
Aurobindo Pharma Approves Merger of Wholly Owned API Subsidiaries Aurobindo Pharma鈥檚 board approved a Scheme of Amalgamation to merge its wholly owned subsidiary Auroactive Pharma (FY26 turnover: INR 701.3m) into Apitoria Pharma (FY26 turnover: INR 64,430.8m), subject to NCLT Hyderabad approval. The swap ratio is set at 97 equity shares of Apitoria Pharma for every 10,000 shares of Auroactive Pharma, totaling 2,395,900 shares. The consolidation aims to integrate API operations, optimize capacity utilization, and simplify group structure, with no change to the parent company's shareholding pattern.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. 路 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. 路 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". 路 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. 路 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. 路 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. 路 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. 路 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. 路 05 Nov 2026
